[go: up one dir, main page]

MA47719A - Esketamine pour le traitement de la dépression - Google Patents

Esketamine pour le traitement de la dépression

Info

Publication number
MA47719A
MA47719A MA047719A MA47719A MA47719A MA 47719 A MA47719 A MA 47719A MA 047719 A MA047719 A MA 047719A MA 47719 A MA47719 A MA 47719A MA 47719 A MA47719 A MA 47719A
Authority
MA
Morocco
Prior art keywords
esketamine
depression
treatment
Prior art date
Application number
MA047719A
Other languages
English (en)
Inventor
Carla Canuso
Ella Daly
Wayne Drevets
David Wood Hough
Adam Janik
Honglan Li
Rachel Ochs-Ross
Jaskaran Singh
Ewa Wajs
Peter Zannikos
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47719A publication Critical patent/MA47719A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047719A 2017-12-22 2018-12-21 Esketamine pour le traitement de la dépression MA47719A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762609504P 2017-12-22 2017-12-22
US201862663206P 2018-04-26 2018-04-26
US201862663219P 2018-04-26 2018-04-26
US201862667406P 2018-05-04 2018-05-04
US201862675846P 2018-05-24 2018-05-24
US201862755905P 2018-11-05 2018-11-05

Publications (1)

Publication Number Publication Date
MA47719A true MA47719A (fr) 2020-01-15

Family

ID=65003585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047719A MA47719A (fr) 2017-12-22 2018-12-21 Esketamine pour le traitement de la dépression

Country Status (16)

Country Link
US (3) US11707440B2 (fr)
EP (1) EP3501542A1 (fr)
JP (2) JP2021506924A (fr)
KR (2) KR20240011237A (fr)
CN (2) CN112423789A (fr)
AU (2) AU2018282466A1 (fr)
BR (1) BR112020012473A2 (fr)
CA (1) CA3086478A1 (fr)
IL (2) IL319020A (fr)
JO (1) JOP20200156A1 (fr)
MA (1) MA47719A (fr)
MX (2) MX2020006650A (fr)
PH (1) PH12020500555A1 (fr)
SG (1) SG11202005896WA (fr)
TW (2) TW202415363A (fr)
WO (1) WO2019126108A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
AU2019293515B2 (en) 2018-06-27 2024-10-24 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
MX2021010683A (es) * 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3976012T3 (pl) * 2019-05-31 2024-06-24 Afyx Therapeutics A/S Donosowe podawanie ketaminy pacjentom z klasterowym bólem głowy
WO2021026232A1 (fr) * 2019-08-05 2021-02-11 The Ketamine Research Foundation Kétamine pour le traitement de symptômes et de troubles post-partum
JP2022546456A (ja) * 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20220339123A1 (en) * 2019-09-13 2022-10-27 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
TW202135787A (zh) * 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137148A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement de troubles neuropsychiatriques ou neurologiques
WO2021137147A1 (fr) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CA3191160A1 (fr) * 2020-08-18 2022-02-24 Oakwood Laboratories, Llc Formulations de microspheres comprenant de la ketamine et leurs procedes de preparation et leurs methodes d'utilisation
CA3199076A1 (fr) * 2020-10-22 2022-04-28 Tonix Pharmaceuticals Holding Corp. Procedes de respect de randomisation pour evaluer la signification d'interventions sur des resultats dans des troubles
US20250248951A1 (en) * 2022-04-26 2025-08-07 Yichang Humanwell Pharmaceutical Co., Ltd. Esketamine liquid preparation and use thereof
WO2024201274A1 (fr) * 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Eskétamine destinée à être utilisée dans le traitement de la dépression
WO2024263816A2 (fr) * 2023-06-21 2024-12-26 Cristcot Llc Développement et validation de mesure d'impact de symptômes d'une maladie hémorragique
WO2025106879A1 (fr) * 2023-11-15 2025-05-22 Gilgamesh Pharmaceuticals, Inc. Méthodes de traitement de troubles psychiatriques ou de la douleur à l'aide de (r)-2-(4-fluorophényl)-2-(méthylamino) cyclohexan-1-one ou de sels pharmaceutiquement acceptables de ceux-ci
US20250241873A1 (en) * 2024-01-26 2025-07-31 Inesket Llc Ketamine nasal spray formulation and methods of use

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10025A (en) 1853-09-20 Improvement in turbines
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
JP4173538B2 (ja) 1995-02-24 2008-10-29 スチュアート エル ウェグ 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与
WO1997007750A1 (fr) 1995-08-30 1997-03-06 Weg Stuart L Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
PT1113785E (pt) 1998-07-24 2005-08-31 Seo Hong Yoo Solucoes aquosas limpidas de acidos biliares
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (fr) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
AU2001291159A1 (en) 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
CA2529857A1 (fr) 2002-07-30 2004-02-05 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040248964A1 (en) 2002-11-18 2004-12-09 Crooks Peter A. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
EP2526987A3 (fr) 2005-06-01 2013-04-24 SHL Group AB Dispositif pour administrer un médicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
CN101466364A (zh) 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
WO2007123945A2 (fr) 2006-04-21 2007-11-01 Aradigm Corporation Dispositif monodose de distribution intrapulmonaire de médicaments
BRPI0711872A2 (pt) 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
AU2011267474B2 (en) 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013056229A1 (fr) 2011-10-14 2013-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation de (2r, 6r)-hydroxynorkétamine, (s)-déshydronorkétamine et autres métabolites déshydro et hydroxylés stéréo-isomères de (r,s)-kétamine dans le traitement de la dépression et de la douleur neuropathique
CN104053785A (zh) 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
CN104519878A (zh) 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013149102A1 (fr) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprenant de la scopolamine et de la kétamine dans le traitement de la dépression
WO2014020155A1 (fr) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Formes d'administration transmuqueuse orale de kétamine s
CN104902883A (zh) 2012-08-23 2015-09-09 斯图亚特·L·韦格 抗焦虑组合物、制剂及使用方法
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
KR102424765B1 (ko) 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
WO2015031410A1 (fr) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Dose orale à couche unique de kétamine neuro-atténuante
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (fr) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Compositions et préparations combinées pour le traitement des douleurs oropharyngées
EP3094312B1 (fr) 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprenant de la kétamine pour le traitement d'un trouble du spectre de l'autisme
ES2935800T3 (es) 2014-04-17 2023-03-10 Ketabon Gmbh Forma de dosificación oral de ketamina
KR102577250B1 (ko) 2014-05-04 2023-09-11 피르메니히 에스아 가향 식품 및 음료 제품
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
US10098854B2 (en) * 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
WO2016109427A1 (fr) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Procédé de maintien de l'effet antidépresseur de la kétamine avec du lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
EP3297620A4 (fr) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC Système d'administration transdermique de la kétamine
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CN112423789A (zh) 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮

Also Published As

Publication number Publication date
BR112020012473A2 (pt) 2020-11-24
TW202415363A (zh) 2024-04-16
CA3086478A1 (fr) 2019-06-27
TW201940162A (zh) 2019-10-16
KR20200113197A (ko) 2020-10-06
AU2018282466A1 (en) 2019-07-11
CN112423789A (zh) 2021-02-26
NZ765616A (en) 2024-12-20
KR20240011237A (ko) 2024-01-25
JP2021506924A (ja) 2021-02-22
IL319020A (en) 2025-04-01
IL275482A (en) 2020-08-31
MX2020006650A (es) 2020-11-06
IL275482B1 (en) 2025-03-01
JOP20200156A1 (ar) 2022-10-30
US11707440B2 (en) 2023-07-25
TWI843711B (zh) 2024-06-01
RU2020123893A3 (fr) 2022-04-29
MX2023012450A (es) 2023-10-31
PH12020500555A1 (en) 2021-05-17
US20210386688A1 (en) 2021-12-16
US20250332121A1 (en) 2025-10-30
RU2020123893A (ru) 2022-01-24
JP2024001204A (ja) 2024-01-09
AU2024227438A1 (en) 2024-11-07
US20240000728A1 (en) 2024-01-04
EP3501542A1 (fr) 2019-06-26
CN117531017A (zh) 2024-02-09
SG11202005896WA (en) 2020-07-29
WO2019126108A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3328374A4 (fr) Antagonistes de la glutamine pour le traitement de déficits cognitifs
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3766497A4 (fr) Médicament pour le traitement de la toux